News

Cardiorespiratory fitness showed the strongest association with gait parameters for women with fibromyalgia.

Patients in the Mediterranean diet group reported improvements in most fibromyalgia measures, including anxiety, fatigue, and disability scores.

A new study highlights the importance of daily antioxidant intake for endometriosis-related RA.

Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.

At 6 months, patients treated with ReNu exhibited significant reductions in assessed knee pain and maintained patient function compared with controls.

This month's review showcases the ongoing efforts to enhance patient care through innovative treatments and comprehensive management strategies.

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.

Lasso demonstrated advantages in predicting clinical remission in patients with RA treated with TNF, with a specificity of 69.9% and sensitivity of 61.7%.

People with diabetes exhibit significantly greater odds of developing carpal tunnel syndrome compared with non-diabetic individuals.

Patients placed in the intervention group reported significant improvements in gout knowledge levels over time compared with controls throughout the 24-week study period.

Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.

Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.

Monosodium urate deposits significantly increased the risk of major cardiovascular events in patients with gout and hyperuricemia.

Internal dysbiosis was present in 66% of patients at baseline and was more common among those with a disease duration of > 2 years.

Patients with RA reported worse outcomes for all PROMs compared with CSA or UA.

Among the nurse-led cohort, 83% of patients with gout achieved target p-urate levels and 98% continued treatment with urate lowering therapy.

The incidence of gout was 2.9 per 1000 patient-years, which dropped by 30% at the beginning of the COVID-19 pandemic.

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population.

Strategies designed to promote medication adherence were found in only 1 out of 3 websites.

Patients receiving abatacept experienced smaller increases in mean IMT, max IMT, and plaque score compared with the csDMARD cohorts.

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

An observational study in the UK investigated the risk of adverse events related to colchicine prophylaxis after receiving allopurinol for gout.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.

After being prescribed another urate lowering therapy for ≥ 30 days, only 51.0% of patients were able to achieve SU < 6 mg/dL.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.

Prolonged modified fasting, in a multimodal medical approach, may help patients with fibromyalgia improve pain and psychosomatic symptoms.

An extension study showed upadacitinib 15 mg and 30 mg for rheumatoid arthritis continues to be favorable, with many patients achieving remission.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.

A propensity score-matched, new-user analysis suggests SGLT2 inhibitors may reduce gout risk in type 2 diabetes patients relative to other second-line therapies.